Introduction {#H1-1-ZOI200356}
============

Substance use disorders (SUDs) represent a pressing public health concern, which calls for clinicians and scientists to identify and implement best practices in treatment.^[@zoi200356r1],[@zoi200356r2]^ To that end, the combination of pharmacological and behavioral interventions has long been considered the criterion standard in addiction care,^[@zoi200356r3],[@zoi200356r4],[@zoi200356r5]^ although differences between best practices for alcohol use disorder (AUD) and SUD have been noted.^[@zoi200356r6]^ For SUDs without a US Food and Drug Administration (FDA)--approved pharmacotherapy, such as cocaine, methamphetamine, and cannabis, behavioral treatments are the principal approach.^[@zoi200356r7]^ Cognitive behavioral therapy (CBT) is a first-line behavioral approach for treating AUD and other SUDs (AUD/SUD).^[@zoi200356r8]^ Cognitive behavioral therapy is a time-limited, multisession intervention that targets cognitive, affective, and environmental risks for substance use and provides training in behavioral self-control skills to help an individual achieve and maintain abstinence or harm reduction.

Despite the importance of combined pharmacological and behavioral interventions for AUD/SUD, few meta-analyses on this intervention approach have been performed. Typically, meta-analytic reviews in the AUD/SUD literature have been conducted on specific pharmacotherapies,^[@zoi200356r9]^ groups of pharmacotherapies,^[@zoi200356r10],[@zoi200356r11],[@zoi200356r12]^ or specific behavioral interventions, such as CBT. As a result, the evidence-informed guideline will relate only to the selection of a single, stand-alone therapy, whether pharmacological or behavioral, and not their combination. For example, in a review of 122 clinical trials of AUD pharmacotherapies delivered in outpatient settings,^[@zoi200356r10]^ the authors could not conclude about the efficacy of pharmacotherapies when combined with a behavioral cointervention.

The meta-analytic evidence on CBT supports efficacy at short- and long-term follow-ups.^[@zoi200356r13]^ In an early review (1999) of 26 studies by Irvin et al,^[@zoi200356r14]^ the authors found CBT to be generally effective across a range of conditions, but effect sizes were roughly 5 times higher when CBT was combined with pharmacotherapy than when delivered as a stand-alone intervention. This subgroup analysis was based on 4 studies and should therefore be interpreted with caution.^[@zoi200356r14]^ In 2009, Magill and Ray^[@zoi200356r15]^ followed up this work with a meta-analysis of 53 CBT clinical trials, reporting a similar overall effect size and a larger effect when CBT was combined with pharmacotherapy than when delivered alone, but the difference in effect-size magnitude between groups was smaller than observed in the previous review including 13 studies.

The goal of this meta-analysis is to provide an up-to-date and comprehensive review of CBT in conjunction with pharmacotherapy for AUD/SUD. This meta-analysis provides effect-size estimates across 3 distinct subgroups that may be informative to best-practice guidelines or individual clinician decision-making: (1) CBT plus pharmacotherapy compared with usual care (eg, clinical management, nonspecific drug counseling) plus pharmacotherapy, (2) CBT plus pharmacotherapy compared with another specific therapy (eg, motivational enhancement therapy, contingency management) plus pharmacotherapy, and (3) CBT added to usual care and pharmacotherapy compared with usual care and pharmacotherapy alone. Sensitivity analyses included tests of heterogeneity, study influence, and publication bias. Given the robust literature on CBT for addiction,^[@zoi200356r15],[@zoi200356r16]^ the critical role of pharmacotherapy in addiction treatment,^[@zoi200356r1],[@zoi200356r2],[@zoi200356r17],[@zoi200356r18],[@zoi200356r19]^ and the notion that combined treatments may be most effective,^[@zoi200356r3],[@zoi200356r17],[@zoi200356r18]^ this meta-analytic review seeks to inform clinical practice and best-practice guidelines for addiction.

Methods {#H1-2-ZOI200356}
=======

Literature Search Strategy {#H2-1-ZOI200356}
--------------------------

A literature search was conducted by a trained research assistant (J.W.) through July 31, 2019, as part of a broader meta-analysis project on CBT for substance use. First, we performed an all-fields search by treatment (*cognitive behavioral therapy* OR *relapse prevention* OR *coping skills training*), outcome (*alcohol* OR *cocaine* OR *methamphetamine* OR *stimulant* OR *opiate* OR *heroin* OR *opioid* OR *marijuana* OR *cannabis* OR *illicit drug* OR *substances* OR *dual disorder* OR *polysubstance* OR *dual diagnosis*), and study terms (*efficacy* OR *randomized controlled trial* OR *randomized clinical trial*) in the PubMed database. Then, we searched the Cochrane Register, Embase, and EBSCO databases (ie, MEDLINE and PsychINFO). Abstract screening was performed by 2 raters in abstrkr.^[@zoi200356r20]^ A bibliographic search of CBT reviews was also performed to identify any candidate studies not identified by the original search methods^[@zoi200356r14],[@zoi200356r16],[@zoi200356r21],[@zoi200356r22],[@zoi200356r23],[@zoi200356r24]^ This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) reporting guideline.

The [Figure](#zoi200356f1){ref-type="fig"} summarizes study inclusion for the present report on combined CBT and pharmacological interventions for adult AUD/SUD (PRISMA diagram). The final meta-analytic sample consisted of 30 studies and 62 effect sizes. No studies that fit the search criteria have been published since 2016. The protocol for this meta-analysis was not registered but was scientifically reviewed at the National Institutes of Health.

![Flow of Study Inclusion (PRISMA Diagram)\
CBT indicates cognitive behavioral therapy.\
^a^Includes studies diverted to other meta-analytic reports on CBT without pharmacotherapy, technology-delivered CBT, and CBT with dual-disorder populations.](jamanetwopen-3-e208279-g001){#zoi200356f1}

Primary Study Inclusion {#H2-2-ZOI200356}
-----------------------

Studies were English-language, peer-reviewed articles published from January 1, 1990, through July 31, 2019. Studies were primary outcome reports of randomized clinical trials. Given the importance of experimental contrast type in estimating effect-size magnitude in clinical trials,^[@zoi200356r25],[@zoi200356r26]^ we used this design factor as a primary subgroup variable. Studies were included if they targeted adult populations (aged ≥18 years) meeting criteria for AUD or other drug use disorder (ie, *Diagnostic and Statistical Manual of Mental Disorders,* Third Edition Revised through Fifth Edition) or problematic use.^[@zoi200356r27]^ Treatment must have been identified as either cognitive behavioral or relapse prevention. Concomitant treatment with pharmacotherapy for AUD/SUD was required for inclusion. Studies of CBT delivered in either individual or group format were included.

Primary Study Characteristic Variables {#H2-3-ZOI200356}
--------------------------------------

Several study characteristic variables were examined in this meta-analysis. Study-level descriptors were mean (SD) age, percentage of female participants, percentage of white participants, percentage of black participants, percentage of Latinx participants, primary drug outcome (ie, alcohol, cocaine/stimulants, opioids, other), substance use severity (ie, dependence, abuse, or heavy use), treatment length (ie, number of planned sessions), treatment delivery (ie, individual or group format), study context (ie, community sample, specialty substance use or mental health clinic, medical setting, college setting, criminal justice setting, or other setting), publication country (ie, United States or other), and study-level risk of bias.^[@zoi200356r28]^ Effect-size subgroup variables were (1) type of experimental contrast (ie, CBT plus pharmacotherapy compared with usual care plus pharmacotherapy, CBT plus pharmacotherapy compared with another specific therapy plus pharmacotherapy, CBT added to usual care and pharmacotherapy compared with usual care and pharmacotherapy alone), (2) type of substance use outcome type (ie, frequency and quantity), and (3) outcome point (posttreatment or follow-up). Data extraction guidelines were detailed in a study codebook available on request. Data were extracted in 2 independent passes conducted by trained raters (L.A.R., L.R.M., and J.W.). Final data entry where disagreement was observed required a consensus review by another author (M.M.).

Primary Study Outcome Variables {#H2-4-ZOI200356}
-------------------------------

The standardized mean difference was used to measure efficacy outcomes in this meta-analysis. The Hedges *g* statistic includes a correction for a slight upward bias in the estimated population effect.^[@zoi200356r29]^ Before pooling, effect sizes were weighted by the inverse of the estimate variance to allow larger studies more influence on the overall effect size.^[@zoi200356r30]^ Primary studies typically provided data on more than 1 outcome; therefore, data for effect-size estimation were selected based on a decisional hierarchy in the following order: (1) biological assay measures, (2) measures of frequency or quantity in the form of means (SDs), (3) sample proportions, and (4) other outcomes (eg, diagnostic measures). Most studies reported posttreatment outcomes only (18 \[60%\]), and if multiple months of follow-up data were reported, the latest time point was selected. Effect sizes were reverse scored as needed (eg, number of days with alcohol use) such that a positive effect size indicated a positive treatment outcome. Finally, when univariate outcome data were not reported, test statistics were transformed using available formulae.^[@zoi200356r31]^ Effect size magnitude was interpreted using the follow benchmarks: 0.2 indicates small; 0.5, medium; and 0.8, large.^[@zoi200356r32]^

Statistical Analysis {#H2-5-ZOI200356}
--------------------

Data were analyzed through September 30, 2019. Comprehensive Meta-analysis, version 3.0,^[@zoi200356r33]^ was used for all analyses. Effect sizes for alcohol and other drug use were pooled using a random-effects model where there was an assumed distribution for the population effect size with systematic and random sources of variability.^[@zoi200356r34]^ The significance of the *Q* test determined whether statistically significant between-study heterogeneity was present, and the *I^2^* statistic provided a percentage of heterogeneity estimate, regardless of statistical significance. When *I^2^* estimates exceeded 50%,^[@zoi200356r33]^ primary drug outcome was tested as an effect-size moderator. We conducted other sensitivity analyses, including trimmed estimates with influential studies (ie, a study that, if removed, would change the substantive interpretation of the pooled effect size) removed and tests for publication bias.

Results {#H1-3-ZOI200356}
=======

Sample-Level Descriptive Data {#H2-6-ZOI200356}
-----------------------------

The sample included 30 unique AUD/SUD randomized clinical trials^[@zoi200356r3],[@zoi200356r7],[@zoi200356r35],[@zoi200356r36],[@zoi200356r37],[@zoi200356r38],[@zoi200356r39],[@zoi200356r40],[@zoi200356r41],[@zoi200356r42],[@zoi200356r43],[@zoi200356r44],[@zoi200356r45],[@zoi200356r46],[@zoi200356r47],[@zoi200356r48],[@zoi200356r49],[@zoi200356r50],[@zoi200356r51],[@zoi200356r52],[@zoi200356r53],[@zoi200356r54],[@zoi200356r55],[@zoi200356r56],[@zoi200356r57],[@zoi200356r58],[@zoi200356r59],[@zoi200356r60],[@zoi200356r61],[@zoi200356r62]^ that examined CBT in combination with some form of pharmacotherapy. The study publication range was 1992 to 2016. The median sample size was 82 participants, with a range of 30^[@zoi200356r35]^ to 917.^[@zoi200356r3]^ The primary substance targeted in these clinical trials was alcohol (15 \[50%\]), followed by cocaine (7 \[23%\]) and opioids (6 \[20%\]). The sample mean (SD) participant age was 39 (6) years, with a mean (SD) of 28% (12%) female participants. Although reporting of race and ethnicity were inconsistent, the mean (SD) percentages were as follows: 66% (26%) white (21 of 30 studies), 35% (28%) black (15 of 30 studies), and 9% (7%) Latinx (15 of 30 studies). Diagnostically, study inclusion primarily (ie, 95%) targeted individuals with abuse or dependence as defined by *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition) criteria.^[@zoi200356r63]^ The CBT portion of these combined interventions was 73% individual and 26% group delivered, and 1 study^[@zoi200356r36]^ used a mixture of individual and group sessions. The mean number of planned sessions was 16 (range, 4-48), and recruitment contexts were primarily specialty substance use or mental health clinics (20 \[68%\]), medical settings (5 \[16%\]), and community advertising (5 \[16%\]). The following pharmacotherapies were examined in this review: naltrexone hydrochloride and/or acamprosate sodium (26 of 62 effect sizes \[42%\]), methadone hydrochloride or combined buprenorphine hydrochloride and naltrexone (Suboxone) (11 of 62 \[18%\]), disulfiram (5 of 62 \[8%\]), and another pharmacotherapy or a mixture of pharmacotherapies (20 of 62 \[32%\]) (see [Table 1](#zoi200356t1){ref-type="table"} and [Table 2](#zoi200356t2){ref-type="table"} for details). Study-level risk-of-bias assessment showed 18 studies (60%) were low risk.^[@zoi200356r28]^ When studies were designated as unclear or high risk, this was typically owing to (1) the presence of baseline differences between conditions, (2) no report of blinding of personnel and participants, and (3) no report of blinding of outcome assessment. Finally, most studies (21 \[70%\]) were published in the United States. Of studies conducted outside the United States, the following countries were represented: Germany, Sweden, the Netherlands, Switzerland, Finland, China, and Australia.

###### CBT Combined With Pharmacotherapy Efficacy at Posttreatment by Type of Contrast Condition

  Source                                                                            No. of participants[^a^](#zoi200356t1n1){ref-type="table-fn"}   Study treatment (No. of sessions)                          Contrast treatment                                 Medication used                        Substance used   Outcome[^b^](#zoi200356t1n2){ref-type="table-fn"}   Risk of bias[^c^](#zoi200356t1n3){ref-type="table-fn"}   *g* statistic (SE)[^d^](#zoi200356t1n4){ref-type="table-fn"}
  --------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------- -------------------------------------- ---------------- --------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------
  **CBT plus pharmacotherapy vs usual care plus pharmacotherapy**                                                                                                                                                                                                                                                                                                                                                                      
  Balldin et al,^[@zoi200356r43]^ 2003                                              56                                                              CBT (9)                                                    Supportive therapy                                 Naltrexone                             Alcohol          Days used                                           Low                                                      0.46 (0.27)
  Balldin et al,^[@zoi200356r43]^ 2003                                              56                                                              CBT (9)                                                    Supportive therapy                                 Naltrexone                             Alcohol          Heaving drinking days                               Low                                                      0.52 (0.27)
  Carroll et al,^[@zoi200356r44]^ 1994                                              54                                                              Relapse prevention (12)                                    Clinical management                                Desipramine hydrochloride              Cocaine          Days abstinent                                      Low                                                      0.21 (0.27)
  Carroll et al,^[@zoi200356r45]^ 1998                                              53                                                              CBT (12)                                                   Clinical management                                Disulfiram                             Alcohol          Continuous weeks abstinent                          Unclear                                                  0.18 (0.28)
  Carroll et al,^[@zoi200356r45]^ 1998                                              53                                                              CBT (12)                                                   Clinical management                                Disulfiram                             Cocaine          Continuous weeks abstinent                          Unclear                                                  0.47 (0.28)
  O'Malley et al,^[@zoi200356r46]^ 1992                                             52                                                              Relapse prevention (12)                                    Supportive therapy                                 Naltrexone                             Alcohol          Days used                                           High                                                     0.01 (0.29)
  O'Malley et al,^[@zoi200356r46]^ 1992                                             52                                                              Relapse prevention (12)                                    Supportive therapy                                 Naltrexone                             Alcohol          Drinks per drinking day of consumption              High                                                     0.60 (0.44)
  O'Malley et al,^[@zoi200356r47]^ 2003                                             190                                                             CBT (10)                                                   Primary care management                            Naltrexone                             Alcohol          Days abstinent                                      Unclear                                                  0.06 (0.15)
  O'Malley et al,^[@zoi200356r47]^ 2003                                             190                                                             CBT (10)                                                   Primary care management                            Naltrexone                             Alcohol          Drinks per drinking day                             Unclear                                                  0.04 (0.15)
  Schmitz et al,^[@zoi200356r48]^ 2001                                              44                                                              Relapse prevention (20)                                    Drug counseling                                    Naltrexone                             Cocaine          Percentage with negative urine screen               Unclear                                                  2.20 (1.10)
  Schmitz et al,^[@zoi200356r49]^ 2004                                              40                                                              Relapse prevention (20)                                    Drug counseling                                    Naltrexone                             Alcohol          Days used                                           Unclear                                                  0.49 (0.32)
  Schmitz et al,^[@zoi200356r49]^ 2004                                              40                                                              Relapse prevention (20)                                    Drug counseling                                    Naltrexone                             Cocaine          Percentage with positive urine screen               Unclear                                                  −0.26 (0.31)
  Schmitz et al,^[@zoi200356r49]^ 2004                                              40                                                              Relapse prevention (20)                                    Drug counseling                                    Naltrexone                             Alcohol          Drinks per day of consumption                       Unclear                                                  0.68 (0.32)
  Wetzel et al,^[@zoi200356r37]^ 2004                                               121                                                             CBT (24)                                                   Group counseling                                   Nefazodone                             Alcohol          Days abstinent                                      Low                                                      0.13 (0.20)
  Wetzel et al,^[@zoi200356r37]^ 2004                                               121                                                             CBT (24)                                                   Group counseling                                   Nefazodone                             Alcohol          Consumption, g/d                                    Low                                                      0.17 (0.20)
  **CBT plus pharmacotherapy vs specific therapy plus pharmacotherapy**                                                                                                                                                                                                                                                                                                                                                                
  Anton et al,^[@zoi200356r50]^ 2005                                                80                                                              CBT (12)                                                   Motivational enhancement therapy                   Naltrexone                             Alcohol          Days abstinent                                      Low                                                      0.57 (0.23)
  Anton et al,^[@zoi200356r50]^ 2005                                                80                                                              CBT (12)                                                   Motivational enhancement therapy                   Naltrexone                             Alcohol          Drinks per drinking day                             Low                                                      0.19 (0.22)
  Carroll et al,^[@zoi200356r45]^ 1998                                              51                                                              CBT (12)                                                   12-step facilitation                               Disulfiram                             Alcohol          Continuous weeks abstinent                          Unclear                                                  −0.06 (0.28)
  Carroll et al,^[@zoi200356r45]^ 1998                                              51                                                              CBT (12)                                                   12-step facilitation                               Disulfiram                             Cocaine          Continuous weeks abstinent                          Unclear                                                  0.18 (0.28)
  Carroll et al,^[@zoi200356r7]^ 2004                                               60                                                              CBT (12)                                                   Interpersonal psychotherapy                        Disulfiram                             Cocaine          Percentage with positive urine screen               Unclear                                                  0.25 (0.26)
  Davidson et al,^[@zoi200356r51]^ 2007                                             149                                                             Broad-spectrum treatment (12)                              Motivational enhancement therapy                   Naltrexone                             Alcohol          Days abstinent                                      Unclear                                                  0.25 (0.16)
  Davidson et al,^[@zoi200356r51]^ 2007                                             149                                                             Broad-spectrum treatment (12)                              Motivational enhancement therapy                   Naltrexone                             Alcohol          Heavy drinking days                                 Unclear                                                  0.05 (0.16)
  De Wildt et al,^[@zoi200356r52]^ 2002                                             170                                                             Brief CBT (7)                                              Motivational enhancement                           Acamprosate                            Alcohol          Days abstinent                                      Low                                                      −0.09 (0.16)
  Epstein et al,^[@zoi200356r41]^ 2003                                              95                                                              CBT (12)                                                   Contingency management                             Methadone                              Cocaine          Times use per day                                   Low                                                      −0.61 (0.21)
  Ling et al,^[@zoi200356r53]^ 2013                                                 102                                                             CBT (16)                                                   Contingency management                             Buprenorphine                          Opioid           Percentage with negative urine screen               Low                                                      −0.10 (0.20)
  Oslin et al,^[@zoi200356r54]^ 2008                                                81                                                              CBT (18)                                                   BRENDA[^e^](#zoi200356t1n5){ref-type="table-fn"}   Naltrexone                             Alcohol          Heavy drinking days                                 High                                                     0.76 (0.24)
  Otto et al,^[@zoi200356r55]^ 2014                                                 78                                                              CBT for interoceptive cues (15)                            Cocaine collaborative individual drug counseling   Methadone                              Opioid           Percentage with negative urine screen               Low                                                      −0.13 (0.34)
  Pettinati et al,^[@zoi200356r56]^ 2008                                            82                                                              CBT (12)                                                   BRENDA[^e^](#zoi200356t1n5){ref-type="table-fn"}   Naltrexone                             Poly drug use    Percentage with negative urine screen               Unclear                                                  0.00 (0.22)
  Rawson et al,^[@zoi200356r57]^ 2002                                               60                                                              Group CBT (48)                                             Contingency management                             Methadone                              Cocaine          Percentage with negative urine screen               Low                                                      −0.44 (0.29)
  **CBT plus usual care plus pharmacotherapy vs usual care plus pharmacotherapy**                                                                                                                                                                                                                                                                                                                                                      
  Anton et al,^[@zoi200356r3]^ 2006[^f^](#zoi200356t1n6){ref-type="table-fn"}       917                                                             Combined behavioral intervention (20) plus MM              MM                                                 Acamprosate and/or naltrexone          Alcohol          Days abstinent                                      Low                                                      −0.06 (0.11)
  Anton et al,^[@zoi200356r3]^ 2006[^f^](#zoi200356t1n6){ref-type="table-fn"}       917                                                             Combined behavioral intervention (20) plus MM              MM                                                 Acamprosate and/or naltrexone          Alcohol          Heavy drinking days                                 Low                                                      0.08 (0.11)
  Dürsteler-MacFarland et al,^[@zoi200356r35]^ 2013                                 30                                                              Group CBT (12) plus DAM                                    DAM                                                Methylphenidate plus diacetylmorphin   Cocaine          Percentage with negative urine screen               Low                                                      −1.80 (0.42)
  Epstein et al,^[@zoi200356r41]^ 2003                                              97                                                              CBT (12) plus MM                                           MM                                                 Methadone                              Cocaine          Times used per day                                  Low                                                      −0.14 (0.20)
  Ling et al,^[@zoi200356r53]^ 2013                                                 104                                                             CBT (16) plus MM                                           MM                                                 Buprenorphine                          Opioid           Percentage with negative urine screen               Low                                                      −0.03 (0.20)
  Morgenstern et al,^[@zoi200356r40]^ 2012                                          102                                                             Modified behavioral self-control therapy (12) plus BBCET   BBCET                                              Naltrexone                             Alcohol          Heavy drinking days                                 Low                                                      2.90 (0.30)
  Oslin et al,^[@zoi200356r54]^ 2008                                                81                                                              CBT (18) plus MM                                           MM                                                 Naltrexone                             Alcohol          Days drinking                                       High                                                     0.67 (0.24)
  Pan et al,^[@zoi200356r36]^ 2015                                                  240                                                             CBT (32) plus MMT                                          MMT                                                Methadone                              Opioid           Percentage with negative urine screen               Low                                                      0.30 (0.13)
  Rawson et al,^[@zoi200356r57]^ 2002                                               60                                                              Group CBT (48) plus MMT                                    MMT                                                Methadone                              Cocaine          Percentage with negative urine screen               Low                                                      0.44 (0.31)
  Scherbaum et al,^[@zoi200356r42]^ 2005                                            73                                                              Group CBT (20) plus MMT                                    MMT                                                Methadone                              Opioid           Percentage with positive urine screen               Low                                                      −0.12 (0.23)
  Schmitz et al,^[@zoi200356r58]^ 2008                                              53                                                              CBT (12) plus clinical management                          Clinical management                                Levodopa                               Cocaine          Percentage with negative urine screen               Low                                                      0.35 (0.36)
  Tucker et al,^[@zoi200356r59]^ 2004                                               97                                                              Group relapse prevention (12) plus case management         Case management                                    Naltrexone                             Opioid           Days used                                           Low                                                      0.16 (0.20)

Abbreviations: BBCET, brief behavioral compliance enhancement treatment; CBT, cognitive behavioral therapy; DAM, diacetylmorphine maintenance; MM, medication management; MMT, methadone maintenance treatment; SE, standard error.

If an arm of the trial did not contribute an effect contrast, the study-level sample size was adjusted.

Negative outcomes such as days used or number of times used per day were reverse scored such that a positive effect estimate would reflect a positive treatment outcome.

Calculated using the Cochrane Risk of Bias Tool.^[@zoi200356r28]^

Hedges *g* includes a correction for a slight upward bias in the estimated population effect.^[@zoi200356r29]^ Before pooling, effect sizes were weighted by the inverse of the estimate variance to allow larger studies more influence on the overall effect size.^[@zoi200356r30]^ Effect size magnitude was interpreted using the following benchmarks: 0.2 indicates small; 0.5, medium; and 0.8, large.^[@zoi200356r32]^

Described by Starosta et al.^[@zoi200356r64]^

Collapsed COMBINE Study medication conditions to test central contrast of interest to this report.

###### CBT Combined With Pharmacotherapy Efficacy at Follow-up by Type of Contrast Condition

  Source                                                                           No. of patients[^a^](#zoi200356t2n1){ref-type="table-fn"}   Study treatment (No. of sessions)               Contrast treatment                Medication used                 Substance used   Follow-up, mo   Outcome[^b^](#zoi200356t2n2){ref-type="table-fn"}   Risk of bias[^c^](#zoi200356t2n3){ref-type="table-fn"}   *g* statistic (SE)[^d^](#zoi200356t2n4){ref-type="table-fn"}
  -------------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------- --------------------------------- ------------------------------- ---------------- --------------- --------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------
  **CBT plus pharmacotherapy vs usual care plus pharmacotherapy**                                                                                                                                                                                                                                                                                                                                              
  Heinala et al,^[@zoi200356r38]^ 2001                                             63                                                          Cognitive coping skills (4)                     Supportive therapy                Naltrexone                      Alcohol          5               Use, g/wk                                           Low                                                      2.00 (0.31)
  Wetzel et al,^[@zoi200356r37]^ 2004                                              121                                                         CBT (24)                                        Group counseling                  Nefazodone                      Alcohol          9               Days abstinent                                      Low                                                      0.24 (0.20)
  Wetzel et al,^[@zoi200356r37]^ 2004                                              121                                                         CBT (24)                                        Group counseling                  Nefazodone                      Alcohol          9               Use, g/d                                            Low                                                      0.50 (0.20)
  **CBT plus pharmacotherapy vs specific therapy plus pharmacotherapy**                                                                                                                                                                                                                                                                                                                                        
  Ling et al,^[@zoi200356r53]^ 2013                                                102                                                         CBT (16)                                        Contingency management            Buprenorphine                   Opioid           5               Percentage with negative urine screen               Low                                                      −0.06 (0.20)
  Ling et al,^[@zoi200356r53]^ 2013                                                102                                                         CBT (16)                                        Contingency management            Buprenorphine                   Opioid           8               Percentage with negative urine screen               Low                                                      −0.06 (0.20)
  Otto et al,^[@zoi200356r55]^ 2014                                                78                                                          CBT for interoceptive cues (15)                 Individual drug counseling        Methadone                       Opioid           2               Percentage with negative urine screen               Low                                                      −0.09 (0.38)
  Rawson et al,^[@zoi200356r57]^ 2002                                              60                                                          Group CBT (48)                                  Contingency management            Methadone                       Cocaine          9               Percentage with negative urine screen               Low                                                      0.16 (0.28)
  Saunders et al,^[@zoi200356r60]^ 2015                                            50                                                          Integrated CBT (12)                             Individual addiction counseling   Multiple                        Polydrug use     6               Days used                                           Unclear                                                  0.36 (0.28)
  De Wildt et al,^[@zoi200356r52]^ 2002                                            170                                                         Brief CBT (7)                                   Motivational enhancement          Acamprosate                     Alcohol          6               Percentage abstinent                                Low                                                      −0.09 (0.29)
  Longabaugh et al,^[@zoi200356r39]^ 2009                                          99                                                          Broad spectrum therapy (24)                     Motivational enhancement          Naltrexone                      Alcohol          12              Days used                                           Low                                                      −0.44 (0.28)
  Longabaugh et al,^[@zoi200356r39]^ 2009                                          99                                                          Broad spectrum therapy (24)                     Motivational enhancement          Naltrexone                      Alcohol          12              Heavy drinking, d                                   Low                                                      0.34 (0.32)
  **CBT plus usual care plus medication vs usual care plus medication contrast**                                                                                                                                                                                                                                                                                                                               
  Anton et al,^[@zoi200356r3]^ 2006[^e^](#zoi200356t2n5){ref-type="table-fn"}      917                                                         Combined behavioral intervention (20) plus MM   MM                                Acamprosate and/or naltrexone   Alcohol          12              Days abstinent                                      Low                                                      −0.00 (0.11)
  Anton et al,^[@zoi200356r3]^ 2006[^e^](#zoi200356t2n5){ref-type="table-fn"}      917                                                         Combined behavioral intervention (20) plus MM   MM                                Acamprosate and/or naltrexone   Alcohol          12              Heavy drinking, d                                   Low                                                      0.04 (0.11)
  Berner et al,^[@zoi200356r61]^ 2014                                              109                                                         CBT (20) plus MM                                MM                                Acamprosate or naltrexone       Alcohol          18              Time to first lapse                                 Unclear                                                  0.08 (0.21)
  Fiellin et al,^[@zoi200356r62]^ 2013                                             141                                                         CBT (12) plus physician management              Physician management              Buprenorphine                   Opioid           3               Days abstinent                                      Low                                                      −0.00 (0.17)
  Ling et al,^[@zoi200356r53]^ 2013                                                104                                                         CBT (16) plus MM                                MM                                Buprenorphine                   Opioid           5               Percentage with negative urine screen               Low                                                      0.00 (0.20)
  Ling et al,^[@zoi200356r53]^ 2013                                                102                                                         CBT (16) plus MM                                MM                                Buprenorphine                   Opioid           8               Percentage with negative urine screen               Low                                                      0.00 (0.20)
  Rawson et al,^[@zoi200356r57]^ 2002                                              60                                                          Group CBT (48) plus MMT                         MMT                               Methadone                       Cocaine          9               Percentage with negative urine screen               Low                                                      0.76 (0.30)
  Saunders et al,^[@zoi200356r60]^ 2015                                            56                                                          Integrated CBT (12) plus standard care          Standard care                     Multiple                        Polydrug use     6               Days used                                           Unclear                                                  0.69 (0.27)
  Scherbaum et al,^[@zoi200356r42]^ 2005                                           73                                                          Group CBT (20) plus MMT                         MMT                               Methadone                       Opioid           6               Percentage with positive urine screen               Low                                                      0.24 (0.23)
  Tucker et al,^[@zoi200356r59]^ 2004                                              97                                                          Relapse prevention (12) plus case management    Case management                   Naltrexone                      Opioid           3               Days used                                           Low                                                      −0.13 (0.22)

Abbreviations: CBT, cognitive behavioral therapy; MM, medication management; MMT, methadone maintenance treatment; SE, standard error.

If an arm of the trial did not contribute an effect contrast, the study-level sample size was adjusted.

Negative outcomes such as days used or number of times used per day were reverse scored such that a positive effect estimate would reflect a positive treatment outcome.

Calculated using the Cochrane Risk of Bias Tool.^[@zoi200356r28]^

Hedges *g* includes a correction for a slight upward bias in the estimated population effect.^[@zoi200356r29]^ Before pooling, effect sizes were weighted by the inverse of the estimate variance to allow larger studies more influence on the overall effect size.^[@zoi200356r30]^ Effect size magnitude was interpreted using the following benchmarks: 0.2 indicates small; 0.5, medium; and 0.8, large.^[@zoi200356r32]^

Collapsed COMBINE Study medication conditions to test central contrast of interest to this report.

[Tables 1](#zoi200356t1){ref-type="table"} and [2](#zoi200356t2){ref-type="table"} describe each study with respect to key design characteristics and effect sizes and are separated by posttreatment and follow-up outcomes, respectively. For outcomes of interest, biological assay/frequency measures and quantity measures are considered primary, and when available both are reported in [Tables 1](#zoi200356t1){ref-type="table"} and [2](#zoi200356t2){ref-type="table"}. Finally, the sample was distributed in roughly equal thirds with respect to the types of conditions to which combined CBT and pharmacotherapy was compared; narrative results and [Tables 1](#zoi200356t1){ref-type="table"} and [2](#zoi200356t2){ref-type="table"} are organized by these clinically informative subgroups, and given the distinctiveness of these comparator conditions, no overall pooled effect size is reported. For pictorial plot information, see eFigures 1 through 10 in the [Supplement](#note-ZOI200356-1-s){ref-type="supplementary-material"}.

CBT Plus Pharmacotherapy Compared With Usual Care Plus Pharmacotherapy {#H2-7-ZOI200356}
----------------------------------------------------------------------

When CBT plus pharmacotherapy was compared with usual care plus pharmacotherapy, the effect for CBT on posttreatment frequency outcomes was small, homogeneous, and statistically significant (*g = *0.18 \[95% CI, 0.01-0.35\]; *P* = .04; τ^2^* = *0.00, *Q* \> 0.05, *I^2^* = 0%),^[@zoi200356r37],[@zoi200356r43],[@zoi200356r44],[@zoi200356r45],[@zoi200356r46],[@zoi200356r47],[@zoi200356r48],[@zoi200356r49]^ but only 1 study^[@zoi200356r37]^ provided follow-up effect-size data (*g = *0.24 \[95% CI, −0.15 to 0.62\]). For quantity outcomes,^[@zoi200356r37],[@zoi200356r43],[@zoi200356r46],[@zoi200356r47],[@zoi200356r49]^ effects were small to moderate, homogenous, and significant (*g = *0.28 \[95% CI, 0.03-0.54\]; *P* = .03; τ^2^* = *0.03; *Q* \> 0.05; *I^2^* = 31%), and only 2 studies^[@zoi200356r37],[@zoi200356r38]^ provided follow-up effect-size data (*g = *0.50 \[95% CI, 0.01-0.89\] and *g = *2.00 \[95% CI, 1.40-2.60\], respectively). Among the studies in this subgroup, no evidence was found for influential studies or publication bias.

CBT Plus Pharmacotherapy Compared With Another Specific Therapy Plus Pharmacotherapy {#H2-8-ZOI200356}
------------------------------------------------------------------------------------

Studies that compared CBT with another specific therapy suggested no unique benefit of adding CBT to pharmacotherapy compared with other evidence-based modalities. For posttreatment frequency outcomes, effects were homogeneous and nonsignificant (*g = *0.05 \[95% CI, −0.13 to 0.23\]; *P* = .58; τ^2^* = *0.03; *Q* \> 0.05; *I^2^* = 35%).^[@zoi200356r7],[@zoi200356r45],[@zoi200356r50],[@zoi200356r51],[@zoi200356r52],[@zoi200356r53],[@zoi200356r55],[@zoi200356r56],[@zoi200356r57]^ A similar pattern of frequency results was found at follow-up (*g = *−0.02 \[95% CI, −0.29 to 0.26\]; *P* = .89; τ^2^* = *0.03; *Q* \> 0.05; *I^2^* = 11%).^[@zoi200356r39],[@zoi200356r52],[@zoi200356r53],[@zoi200356r57],[@zoi200356r60]^ Quantity posttreatment outcomes were also nonsignificant but statistically heterogeneous (*g = *0.09 \[95% CI, −0.42 to 0.60\]; *P* = .74; τ^2^* = *0.23; *Q* \< 0.05; *I^2^* = 84%).^[@zoi200356r41],[@zoi200356r50],[@zoi200356r51],[@zoi200356r54]^ At follow-up, only Longabaugh et al^[@zoi200356r39]^ reported quantity outcomes (*g = *0.34 \[95% CI, −0.29 to 0.96\]). Sensitivity analyses showed no influential studies or evidence of publication bias.

CBT as an Add-on to Usual Care and Pharmacotherapy Compared With Usual Care and Pharmacotherapy Alone {#H2-9-ZOI200356}
-----------------------------------------------------------------------------------------------------

The final subgroup of studies examined CBT as an add-on to combined usual care and pharmacotherapy and suggested no clear added benefit of CBT in this context. Frequency results were heterogeneous and nonsignificant after treatment (*g = *0.06 \[95% CI, −0.22 to 0.34\]; *P* = .67; τ^2^* = *0.13; *Q* \< 0.05; *I^2^* = 76%)^[@zoi200356r3],[@zoi200356r35],[@zoi200356r36],[@zoi200356r42],[@zoi200356r53],[@zoi200356r54],[@zoi200356r57],[@zoi200356r58],[@zoi200356r59]^ and at follow-up (*g = *0.17 \[95% CI, −0.05 to 0.38\]; *P* = .13; τ^2^* = *0.04; *Q* \> 0.05; *I^2^* = 51%).^[@zoi200356r3],[@zoi200356r42],[@zoi200356r53],[@zoi200356r57],[@zoi200356r59],[@zoi200356r60],[@zoi200356r62]^ Only 3 studies (all AUD trials) provided quantity effect-size data, and these studies showed very different measures of effect (Anton et al^[@zoi200356r3]^: *g* = 0.08 \[95% CI, −0.14 to 0.31\]; Epstein et al^[@zoi200356r65]^: *g = −*0.14 \[95% CI, −0.54 to 0.25\]; Morgenstern et al^[@zoi200356r40]^: *g = *2.90 \[95% CI, 2.32-3.48\]). At follow-up, the effect size for quantity outcomes in the COMBINE Study^[@zoi200356r3]^ was *g = *0.04 (95% CI, −0.19 to 0.26) for collapsed pharmacotherapy, medication management, and combined behavioral intervention conditions vs pharmacotherapy and medication management only conditions. Sensitivity analyses showed no evidence of publication bias but showed 2 influential studies^[@zoi200356r35],[@zoi200356r40]^ (eFigure 3 in the [Supplement](#note-ZOI200356-1-s){ref-type="supplementary-material"}).

Primary Drug Target as a Moderator of Between-Study Heterogeneity {#H2-10-ZOI200356}
-----------------------------------------------------------------

In this review of CBT combined with pharmacotherapy for AUD/SUD frequency and quantity outcomes after treatment and at follow-up, most effect estimates showed little to no statistical heterogeneity. This outcome suggests that the variation between studies within a given pooled effect size was random rather than systematic.^[@zoi200356r33]^ The exception was CBT combined with pharmacotherapy in contrast to another specific therapy combined with pharmacotherapy in relation to posttreatment quantity outcomes (*Q* \< 0.05; *I^2^* = 84%)^[@zoi200356r41],[@zoi200356r50],[@zoi200356r51],[@zoi200356r54]^ and CBT as an addition to combined usual care and pharmacotherapy in relation to posttreatment (*Q* \< 0.05; *I^2^* = 76%)^[@zoi200356r3],[@zoi200356r35],[@zoi200356r36],[@zoi200356r42],[@zoi200356r53],[@zoi200356r54],[@zoi200356r57],[@zoi200356r58],[@zoi200356r59]^ and follow-up (*Q* \> 0.05; *I^2^* = 51%)^[@zoi200356r3],[@zoi200356r42],[@zoi200356r53],[@zoi200356r57],[@zoi200356r59],[@zoi200356r60],[@zoi200356r62]^ frequency outcomes. Given that the sample of studies targeted different substances, each primary drug was examined as a subgroup moderator, and residual *I^2^* values were reported. Results are presented in [Table 3](#zoi200356t3){ref-type="table"}. These analyses show that pooled effect-size direction and/or magnitude varied by primary drug outcome in this review. However, residual heterogeneity was present in 3 of the 8 subgroups, suggesting that this a priori moderator was an informative variable in this meta-analysis but did not explain all the systematic variance between studies. As a result, random-effects estimates are a particularly appropriate metric for this review.

###### Subgroup Analyses of Heterogeneous Pooled Effect Sizes

  Subgroup                                                                                                     *g* statistic (SE)                                       Source             *I^2^,* %
  ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------- ------------------ -----------
  Compared with another specific therapy plus pharmacotherapy in relation to posttreatment quantity outcomes   0.09 (0.26)[^a^](#zoi200356t3n1){ref-type="table-fn"}    ^[@zoi200356r4]^   84
  Alcohol studies                                                                                              0.31 (0.27)                                              ^[@zoi200356r3]^   67
  Cocaine or stimulant studies                                                                                 −0.61 (0.21)[^b^](#zoi200356t3n2){ref-type="table-fn"}   ^[@zoi200356r1]^   NA
  Added to usual care plus pharmacotherapy in relation to posttreatment frequency outcomes                     0.06 (0.14)[^a^](#zoi200356t3n1){ref-type="table-fn"}    ^[@zoi200356r9]^   76
  Alcohol studies                                                                                              0.28 (0.36)                                              ^[@zoi200356r2]^   87
  Opioid studies                                                                                               0.14 (0.09)                                              ^[@zoi200356r4]^   14
  Cocaine or stimulant studies                                                                                 −0.32 (0.67)                                             ^[@zoi200356r3]^   90
  Added to usual care plus pharmacotherapy in relation to follow-up frequency outcomes                         0.17 (0.11)[^a^](#zoi200356t3n1){ref-type="table-fn"}    ^[@zoi200356r7]^   51
  Alcohol studies                                                                                              0.02 (0.10)                                              ^[@zoi200356r2]^   0
  Opioid studies                                                                                               0.02 (0.01)                                              ^[@zoi200356r4]^   0
  Cocaine or stimulant studies                                                                                 0.76 (0.30)[^b^](#zoi200356t3n2){ref-type="table-fn"}    ^[@zoi200356r1]^   NA

Abbreviations: NA, not applicable; SE, standard error.

Indicates the a priori pooled estimates.

*P* \< .05.

Discussion {#H1-4-ZOI200356}
==========

To our knowledge, this is the first targeted meta-analysis of CBT in combination with pharmacotherapy for adults with AUD and other SUDs to summarize the data in a manner relevant to clinical practice guidelines. Furthermore, we provided pooled effect size estimates by consumption outcome type and outcome point. Most of these subgroup estimates showed acceptable homogeneity, which suggests that the selected variables were informative effect-size modifiers for the sample of clinical trials reviewed. In the present study, a small and statistically significant effect size was observed across outcome type and time for CBT combined with pharmacotherapy when compared with usual care combined with pharmacotherapy. For context in interpreting this effect, meta-analyses among this patient population generally show effect sizes that are in the small-to-moderate range,^[@zoi200356r41],[@zoi200356r66],[@zoi200356r67]^ and this includes effect sizes for pharmacological interventions.^[@zoi200356r11],[@zoi200356r68],[@zoi200356r69]^ This contrast suggests that prescribing clinicians should favor CBT over usual care to improve clinical outcomes for addiction, in the context of pharmacotherapy.

The second subgroup contrast was combined CBT and pharmacotherapy compared with another specific therapy combined with pharmacotherapy. Here, results suggested no unique benefit of adding CBT to pharmacotherapy compared with other evidence-based behavioral modalities. Such modalities may include contingency management, motivation enhancement therapy, 12-step facilitation, and interpersonal therapy, all of which have received some level of empirical support for addiction,^[@zoi200356r70],[@zoi200356r71]^ including meta-analytic support at various follow-up periods.^[@zoi200356r23]^ The lack of superiority of CBT over other evidence-based behavioral treatment for addiction is consistent with our recent findings,^[@zoi200356r13]^ and this meta-analysis extends this result to combined pharmacotherapy and behavioral treatments. Although there may be evidence of some advantage for contingency management,^[@zoi200356r72]^ removal of contingency management trials in this review did not change our substantive conclusions. This suggests that CBT is not superior to other evidence-based behavioral treatments for addiction, yet when combined with the aforementioned superiority to usual care, we suggest that clinicians favor an evidence-based behavioral therapy, CBT or otherwise, in conjunction with pharmacological treatments.

The third contrast in this meta-analysis assessed CBT as an add-on to usual care and pharmacotherapy compared with usual care and pharmacotherapy alone. In interpreting these findings, several explanations come to mind. First, there was substantial heterogeneity in the effect sizes obtained in these studies, suggesting unique study-specific factors could further explain outcome variability. This speculation is supported by the 2 influential studies observed in this subgroup.^[@zoi200356r35],[@zoi200356r40]^ Moreover, moderator analyses by primary drug target showed variability in effect-size direction and magnitude with effects for cocaine and stimulant studies showing a range from moderate and negative^[@zoi200356r35],[@zoi200356r41]^ to large and positive^[@zoi200356r57],[@zoi200356r58]^ effects. This variability may be due, in part, to the lack of FDA-approved pharmacotherapy for cocaine/stimulant use disorder.^[@zoi200356r73]^ In other words, FDA approval in this case was potentially confounded with the primary drug target. Second, some studies reported participants' poor adherence to the CBT protocol, which may directly affect outcome.^[@zoi200356r42],[@zoi200356r65]^ Third, the COMBINE Study is a large trial, which reported no benefit of the combined behavioral intervention over medication management. Close inspection of the medication management protocol for this study suggests it was a systematic, intensive, and rather robust intervention^[@zoi200356r74],[@zoi200356r75]^ not readily comparable to standard clinical care. Together, these findings speak to the difficulty of measuring the benefit of an add-on component in complex clinical settings where multiple interventions are simultaneously administered.

Limitations {#H2-11-ZOI200356}
-----------

This study has some limitations to consider. First, our primary goal was to derive valid, random-effects estimates characterized by effect modifiers. In other words, the goal was to avoid combining apples and oranges,^[@zoi200356r76]^ which is a common criticism against meta-analysis. Although we consider our subgroup approach a strength, some effect size estimates were composed of a small number of primary studies, and this may result in underpowered analyses. Second, there may be some concern about fidelity and other sources of variability in what constituted this sample of CBT interventions, given that a range of manual implementations were reviewed. Unfortunately, fidelity to behavioral intervention protocol is often poorly reported in the clinical trial literature^[@zoi200356r77]^ and could not be consistently measured for the present study. Similarly, this meta-analysis did not account for medication compliance or dose as a potential source of variability. The exclusion of 6 non-English articles is another potential limitation of this study. Finally, study results should be considered in the context of what constitutes an optimal outcome in clinical research with adult AUD/SUD. We selected consumption measures and favored biological assay variables in SUD trials, but equally important may be improvements in overall functioning,^[@zoi200356r78]^ in which behavioral therapies, such as CBT, may be more likely to demonstrate effects.^[@zoi200356r18],[@zoi200356r19]^ Therefore, the degree to which the outcomes presented in this review reflect an ideal end point remains an ongoing discussion for the field.

Conclusions {#H1-5-ZOI200356}
===========

Current clinical and research practices suggest that the rationale for combining behavioral therapy and pharmacotherapy is to provide support and skills while the patient is waiting for the medication effects to become apparent, to enhance treatment adherence, to improve treatment and study retention, and to address symptoms and problems that the medication will not address (eg, skills building).^[@zoi200356r18],[@zoi200356r19],[@zoi200356r74]^ In an effort to inform best practices in addiction treatment, the following take-home points are drawn from the results of this meta-analysis. First, our results suggest that prescribing clinicians should favor CBT over usual clinical management to ensure optimal clinical outcomes for addiction, in the context of pharmacotherapy. This conclusion is based in our comparison of CBT plus pharmacotherapy vs usual care plus pharmacotherapy. Second, CBT is not superior to other evidence-based behavioral treatments for addiction, yet in the context of its superiority to usual care, our findings suggest that clinicians should favor an evidence-based behavioral therapy, CBT or otherwise, in conjunction with pharmacological treatment. Third, the add-on benefit of CBT compared with pharmacotherapy and usual care was not clearly supported and suggests that benefit of CBT as an adjunct requires further investigation.
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